Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H30N4O.H3O4P |
Molecular Weight | 464.495 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.CC(C)CCNC1=NC=CC=C1C(=O)N2CCN(CC3=CC=CC=C3)CC2
InChI
InChIKey=LWHMGALTTIYPJU-UHFFFAOYSA-N
InChI=1S/C22H30N4O.H3O4P/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19;1-5(2,3)4/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24);(H3,1,2,3,4)
NSI-189 is a novel oral drug which was developed by Neuralstem for the treatment of cognitive disorders. Now the drug is being tested in phase II of clinical trials in patients suffering from major depressive disorder. The mechanism of NSI-189 action is explained by its ability to stimulate the generation of new neurons in the hippocampus, however the exact target molecule is still unknown.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0022008 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26643541 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1144 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541 |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NSI-189 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2791 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541 |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NSI-189 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4384 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541 |
40 mg 3 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NSI-189 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541 |
40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NSI-189 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
20.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541 |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NSI-189 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541 |
40 mg 3 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NSI-189 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 3 times / day multiple, oral Highest studied dose Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: Page: p.1377 |
unhealthy, 40.5 n = 6 Health Status: unhealthy Condition: Major depressive disorder Age Group: 40.5 Sex: M+F Population Size: 6 Sources: Page: p.1377 |
PubMed
Title | Date | PubMed |
---|---|---|
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. | 2016 Oct |
|
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. | 2016 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02695472
40 mg of NSI-189 are administered orally once or twice daily for 28 days.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
647018
Created by
admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
HX0VO60T62
Created by
admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023
|
PRIMARY | |||
|
50922680
Created by
admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023
|
PRIMARY | |||
|
1270138-41-4
Created by
admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD